Virbac SA (FRA:V16)

Market Cap	2.76B -3.5%
Revenue (ttm)	1.46B +4.8%
Net Income	150.89M +3.9%
EPS	18.00 +3.8%
Shares Out	n/a
PE Ratio	18.27
Forward PE	15.75
Dividend	1.45 (0.45%)
Ex-Dividend Date	Jul 2, 2026

Volume	n/a
Open	322.50
Previous Close	324.00
Day's Range	322.50 - 327.00
52-Week Range	297.00 - 381.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 17, 2026

About Virbac

Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at risk of fleas, ticks, lice, and sandflies; Zenidog/Zenifel offers a fogger, spray, and non-electric ph...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1968
• Employees: 6,442
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: V16

Financial Performance

In 2025, Virbac's revenue was 1.46 billion, an increase of 4.82% compared to the previous year's 1.40 billion. Earnings were 150.89 million, an increase of 3.85%.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error